Ligand-induced rapid skeletal muscle atrophy in HSA-Fv2E-PERK transgenic mice
Fig 4
Altered intercellular amino acid metabolism in AP-injected HSA-Fv2E-PERK Tg mice.
(A) Heatmap representation of amino acid metabolites in gastrocnemius muscles of AP-injected WT and AP-injected Tg mice (n = 5). Colors indicate ratios of determined amino acids contents in vehicle-injected WT mice; the vertical axis is labeled with a continuous scale color bar key. AP (1-μg/kg BW) was injected intraperitoneally. (B) Amino acid concentrations in gastrocnemius muscles of AP-injected WT, vehicle-injected Tg, and AP-injected Tg mice. Vehicle or AP (0.1-mg/kg BW) was intraperitoneally injected once a day for 7 days (n = 5). Differences among AP-treated HSA-Fv2E-PERK Tg mice, vehicle-treated HSA-Fv2E-PERK Tg mice, and AP-treated WT mice were considered significant at *p < 0.05 or **p < 0.01.